Last reviewed · How we verify
NCT06660329
Efficacy and Safety of Tofacitinib in Refractory Blau Syndrome
Phase 4 trial testing Janus Kinase Inhibitor in Blau Syndrome in 30 participants. Enrolling by invitation.
1 October 2027
Quick facts
| Lead sponsor | Peking Union Medical College Hospital |
|---|---|
| Phase | Phase 4 |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 October 2024 |
| Primary completion | 1 October 2027 |
| Estimated completion | 1 October 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Janus Kinase Inhibitor — full drug profile →
Conditions studied
- Blau Syndrome — all drugs for Blau Syndrome →
Sponsor
Peking Union Medical College Hospital
Who can join
Adults 0 to 18, any sex, with Blau Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective cohort study to observe the efficacy and safety of Tofacitinib in children with Blau syndrome (BS). The investigators would analyze the rate of remission or low disease activity after treatment as well as changes in inflammatory markers, patients' and physician's global assessment of disease activity to determine the efficacy and safety of Tofacitinib.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06660329
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Janus Kinase Inhibitor
Trials testing the same drug.
- NCT05451615 — Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis · Phase 3 · unknown
- NCT06561256 — JAK Inhibitors' Efficacy in Bullous Pemphigoid · completed
- NCT04576000 — Identification of Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis · terminated
Other recruiting trials for Blau Syndrome
Currently open trials in the same condition.
- NCT00001244 — Immune Regulation in Patients With Common Variable Immunodeficiency and Related Inborn Errors of Immunity (IEI) · recruiting
Other Peking Union Medical College Hospital trials
Trials by the same sponsor.
- NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
- NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
- NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
- NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
- NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06660329 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
- Last refreshed: 28 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06660329.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing